Latest news with #V.T.
Forbes
17-06-2025
- Health
- Forbes
Aurora Cannabis Faces Class Action Over Cannabinoid Hyperemesis Syndrome Risk
Aurora Cannabis is facing a class action led by a Canadian military veteran, who alleges that the company didn't adequately warn consumers about Cannabis Hyperemesis Syndrome (CHS), a condition the plaintiff says was caused by its products. The class action was certified last month in Ontario's Superior Court of Justice and is being brought by Canadian law firm Sotos Class Actions. It seeks to represent all individuals in Canada who purchased Aurora Cannabis products between February 2015 and May 2025 and were later diagnosed with CHS. Aurora Cannabis, based in Canada, is one of the largest medical cannabis companies in the industry and operates globally, with a presence in North America, Europe, Latin America, and Australia. It als trades on the Toronto Stock Exchange and Nasdaq. In January, the company announced the release of its first medical cannabis product grown in Germany, following the legalization of recreational cannabis for personal use that eased restrictions in the country's medical cannabis market. The plaintiff, identified as V.T., alleges she developed CHS after using Aurora's cannabis products, which were prescribed to treat post-traumatic stress disorder. Cannabinoid Hyperemesis Syndrome (CHS) is a condition tied to long-term cannabis use that leads to repeated bouts of severe vomiting. Since the syndrome hasn't been widely studied, estimates of how many people experience CHS symptoms differ. A study published in Basic & Clinical Pharmacology & Toxicology found that about 33% of long-term cannabis users met the criteria for CHS. According to the claim, V.T. used cannabis oils and softgels daily from 2019 to 2020 as prescribed but later experienced severe and ongoing stomach problems, including repeated nausea, vomiting, and abdominal pain. These symptoms became so intense that V.T. was hospitalized. During the second emergency room visit, V.T. was diagnosed with CHS. She says she wasn't warned about the possible risks and that the product packaging and related materials didn't include any information about the condition. The claim alleges that Aurora and its subsidiaries, namely Aurora Cannabis Enterprises and MedReleaf, either knew or should have known of 'all the serious harmful effects arising from the consumption' but didn't warn consumers or healthcare professionals. 'The Defendants do not publish product monographs for the cannabis products or otherwise direct information to learned professionals, including prescribing physicians or product sales persons, communicating the risk of CHS,' the statement of claim reads. V.T., therefore, accuses the companies of neglecting their duty of care and engaging in misleading practices, claiming they violated both federal and provincial laws, including the Cannabis Act and the Food and Drugs Act, which states that no one is allowed to label, package, sell, or promote a drug in a way that is false, misleading, or likely to give the wrong impression about its nature, value, ingredients, or safety. 'The failure to warn of the risk of CHS of the cannabis products is a false, misleading or deceptive omission about the safety of the cannabis products,' the claim highlights. When asked for comment, an Aurora spokesperson said by email that the company does not comment on legal matters beyond what is publicly available. They added that information related to the class action can be found through the company's regular disclosures. In the class action, V.T. is, therefore, seeking general and aggravated damages for pain, emotional distress, and lost income, along with compensation for overpayment and unjust enrichment. The claim also asks for reimbursement of public healthcare costs, class notification expenses, and the return of profits linked to the alleged misconduct. This is one of the first class actions related to CHS and involves a major medical cannabis company. The case raises questions about whether consumers are adequately informed of the potential risks of frequent or long-term cannabis use, and could set a legal precedent for the regulated cannabis industry, particularly concerning emerging health issues.
Cision Canada
13-06-2025
- Health
- Cision Canada
AURORA CANNABIS CHS CLASS ACTION CERTIFIED Français
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death. On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants. The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website. The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS. The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants. The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims. . Sotos Class Actions 55 University Avenue, Suite 600 Toronto, ON M5J 2H7 [email protected] 1-877-294-9747 (toll free) For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at [email protected].
Yahoo
09-06-2025
- Health
- Yahoo
AURORA CANNABIS CHS CLASS ACTION CERTIFIED
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death. On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants. The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website. The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS. The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants. The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims. More information about the class proceeding, including the Plaintiff's Fresh as Amended Statement of Claim, is available on Class Counsel's website: For further information, or if you have been diagnosed with CHS, please contact Class Counsel: Sotos Class Actions 55 University Avenue, Suite 600Toronto, ON M5J 2H7auroracannabisclassaction@ (toll free) For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at mwaddell@ SOURCE Sotos Class Actions View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
09-06-2025
- Health
- Cision Canada
AURORA CANNABIS CHS CLASS ACTION CERTIFIED
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death. On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants. The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website. The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS. The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants. The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims. . Sotos Class Actions 55 University Avenue, Suite 600 Toronto, ON M5J 2H7 [email protected] 1-877-294-9747 (toll free) For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at [email protected].
The Hindu
25-05-2025
- Sport
- The Hindu
Meropi obliges in the feature event
Aashay Doctor-trained Meropi (Trevor up) won the H.H. Jayachamaraja Wadiyar Cup (1,400m), the main event of the races held here on Sunday (May 25). The winner is owned by Mr. Solomon Benveniste, M/s. Deciding Factor LLP, Mrs. Menaka Gupta, Mrs. Rina Mahindra, Mr. Marthand Singh Mahindra, Mr. Hemang D. Doctor, Mr. Viral Doctor & M/S. Cherie Sports Pvt Ltd. Trainer Aravind G. won three races on the day. The results: 1. MOONLIGHT ROMANCE PLATE (1,400m): JOYFUL SPIRIT (Sai Kiran) 1, Sacred Creator (Ramswarup) 2, Chinky Pinky (Aleemuddin) 3 and Thrill Of Brazil (Tauseef) 4. 7-1/2, 2-1/2 and 3/4. 1m, 28.76s. ₹20 (w), 12, 62 and 17 (p), SHP: 195, THP: 35, FP: 463, Q: 432, Trinella: 2,007/595, Exacta: 10,080/5,760. Favourite: Joyful Spirit. Owner: Mr. Nanda Kumar N. Trainer: M. Rajendra Singh. 2. MINISTERIAL PLATE (1,100m): NIGHT RAIDER (Arvind K) 1, Konkrah (Sandesh) 2, Quebec (Trevor) 3 and Allegro Dance (Darshan) 4. 2-1/4, 2 and 2-1/4. 1m, 07.79s. ₹116 (w), 17, 13 and 13 (p), SHP: 41, THP: 62, FP: 1,081, Q: 321, Trinella: 1,277/492, Exacta: 5,573/3,184. Favourite: Quebec. Owners: M/s. Arun Alagappan Racing LLP & Mr. Chandrakanth Kankaria. Trainer: Irfan Ghatala. 3. BEAUTIFUL BABE PLATE (1,400m): MOON STAR (Akshay K) 1, Rosario (G. Vivek) 2, Xanthe (Sandesh) 3 and Sassy Sarah (S. Shareef) 4. Not run: Alamgir. 2-1/4, 5-3/4 and 1-3/4. 1m, 25.63. ₹88 (w), 19, 13 and 14 (p), SHP: 40, THP: 40, FP: 273, Q: 95, Trinella: 453/194, Exacta: 11,771. Favourite: Rosario. Owner: Dr. A.C. Muthiah. Trainer: Aravind G. 4. PENDRAGON PLATE (Div. II), (1,200m): FLASH (Rayan) 1, Legendary Impact (G. Vivek) 2, Basilica (Neeraj) 3 and Selection (Sai Kiran) 4. 5-3/4, 5 and 2-1/4. 1m, 14.14s. ₹147 (w), 29, 13 and 15 (p), SHP: 37, THP: 63, FP: 402, Q: 132, Trinella: 565/216, Exacta: 2,034/1,370. Favourite: Legendary Impact. Owner: Dr. M.A.M. Ramaswamy Chettiar of Chettinad Charitable Trust. Trainer: Aravind G. 5. V.T. VELU MEMORIAL TROPHY (1,600m): ODYSSEUS (Neeraj) 1, Rock Bank (Akshay K) 2, Storm Shadow (S.F. Ansari) 3 and Live The Dream (R. Ajinkya) 4. Not run: Dedication. 1/2, Nose and 2-3/4. 1m, 39.42s. ₹41 (w), 18, 15 and 69 (p), SHP: 45, THP: 144, FP: 129, Q: 56, Trinella: 1,838/2,139, Exacta: 33,237 (carried over)/2,848. Favourite: Eagle Day. Owners: Equus Racing (PF), Mr. Kersi H. Vachha, Mr. Suhrud S. Jhaveri, Gautham Lala rep. Gainsville Stud & Agrl Farm Pvt Ltd & Mr. Berjis Minoo Desai. Trainer: P. Shroff. 6. H.H. JAYACHAMARAJA WADIYAR CUP (1,400m): MEROPI (Trevor) 1, Prana (G. Vivek) 2, Knotty Charmer (Antony) 3 and Miss American Pie (N.S. Parmar) 4. Not run: Magileto. 1/2, 3-1/4 and Snk. 1m, 25.09s. ₹24 (w), 13, 16 and 18 (p), SHP: 43, THP: 55, FP: 72, Q: 41, Trinella: 240/143, Exacta: 2,583/1,476. Favourite: Meropi. Owners: Mr. Solomon Benveniste, M/S. Deciding Factor LLP, Mrs. Menaka Gupta, Mrs. Rina Mahindra, Mr. Marthand Singh Mahindra, Mr. Hemang D. Doctor, Mr. Viral Doctor & M/S. Cherie Sports Pvt Ltd. Trainer: Aashay Doctor. 7. RAMKIRPAL PLATE (1,200m): SPIRIT DANCER (G. Vivek) 1, Lady Invictus (Shreyas S) 2, Oxytocin (R. Pradeep) 3 and Princess Jasmine (Likith Appu) 4. 1-1/4, 1-3/4 and 2-3/4. 1m, 14.78s. ₹53 (w), 15, 24 and 10 (p), SHP: 66, THP: 90, FP: 1,038, Q: 380, Trinella: 1,111/257, Exacta: 9,132/4,696. Favourite: Oxytocin. Owner: Dr. M.A.M. Ramaswamy Chettiar of Chettinad Charitable Trust. Trainer: Aravind G. 8. PENDRAGON PLATE (Div. I), (1,200m): FORTIS (Shreyas S) 1, Sienna Princess (Sai Kiran) 2, True Punch (Ramswarup) 3 and Real Happiness (G. Praveen) 4. 3-3/4, 3-1/4 and 1-1/2. 1m, 14.83s. ₹21 (w), 12, 20 and 27 (p), SHP: 47, THP: 57, FP: 181, Q: 91, Trinella: 812/485, Exacta: 6,298/1,868. Favourite: Fortis. Owner: Manjri Horse Breed Farm Pvt Ltd. Trainer: S. Attaollahi. Jackpot: ₹38,049 (nine tkts.); Runner-up: 7,338 (20 tkts.); Treble (i): 7,157 (two tkts.); (ii): 328 (53 tkts.).
